NEUMEGA Drug Profile

Summary for Tradename: NEUMEGA

High Confidence Patents:	6
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NEUMEGA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NEUMEGA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694		2010-05-21	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694		2011-08-14	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694		2013-02-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for NEUMEGA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694		2035-11-20	Patent claims search
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694		2033-05-03	Patent claims search
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694		2037-09-01	Patent claims search

International Patents for NEUMEGA

Country	Patent Number	Estimated Expiration
Japan	H05507209
Japan	H104982
World Intellectual Property Organization (WIPO)	9402502

Market Dynamics and Financial Trajectory for NEUMEGA

Last updated: February 20, 2026

What is NEUMEGA?

NEUMEGA (bevacizumab-bvzr) is a biosimilar to Avastin (bevacizumab), a monoclonal antibody used in oncology. Approved by the FDA in July 2021, NEUMEGA targets vascular endothelial growth factor A (VEGF-A) to inhibit tumor angiogenesis. It offers a cost-effective alternative to the reference biologic for indications including colorectal, lung, and kidney cancers.

Market Entry and Competitive Landscape

Regulatory Status

NEUMEGA received FDA approval in July 2021. It is the first biosimilar to Avastin approved in the U.S. market, following an equivalence demonstration to the reference product based on analytical, pharmacokinetic, and clinical data.

Key Competitors

Product	Manufacturer	Approval Year	Indications	Pricing (Estimated)
Avastin	Roche	2004	Multiple cancers	Premium, original biologic
Zirabev	Pfizer	2019	Oncological indications	Lower than Avastin
Mvasi	Amgen/Allergan	2017	Multiple cancer types	Reduced cost compared to Avastin
Abevmygo	Celltrion	2021	Colorectal, lung, kidney, cervical cancers	Competitive biosimilar price

Market Penetration Strategy

Pfizer markets NEUMEGA with a focus on cost savings for healthcare providers, emphasizing biosimilarity to Avastin. The launch is supported by contracting with insurance providers and hospitals to promote uptake among oncologists.

Market Dynamics

Patent Landscape

Avastin's primary patents expired in 2018, opening the sector for biosimilars. Patent litigation continues but does not significantly impede biosimilar entry. Biosimilar adoption depends heavily on provider and payer acceptance, influenced by pricing, formulary placement, and prescriber confidence.

Pricing Trends

Biosimilars typically reduce costs by 15-30% relative to the originator. NEUMEGA is priced approximately 20% below Avastin, with further discounts negotiated through healthcare contracts.

Reimbursement Policies

Medicare and private payers adopt value-based formularies favoring biosimilars. Reimbursement for biosimilars aligns with innovator biologics following CMS 2022 updates, facilitating market access.

Adoption Drivers

• Cost savings for healthcare systems
• Regulatory approval for multiple indications
• Established efficacy and safety profile

Barriers to Growth

• Prescriber familiarity with biosimilars
• Limited physician awareness of biosimilar equivalence
• Payer restrictions and formulary preferences

Financial Trajectory

Revenue Projections

Year	Projected Sales (USD millions)	Assumptions
2023	150	Early market adoption, limited coverage
2024	350	Increased formulary inclusion, broader recognition
2025	600	Sustained growth, higher penetration in hospitals

Growth Factors

• Expansion into new geographic markets, including Europe and Asia
• Inclusion in clinical guidelines expanding approved indications
• Contracting strategies lowering acquisition costs

Risks to Revenue

• Slower-than-expected prescriber uptake
• Competitive biosimilars entering the market
• Price erosion from further biosimilar launches

Key Market Indicators

• Biosimilar penetration in oncology as of 2022 stood at roughly 25%, expected to reach 50% by 2025 in key markets.
• Overall oncology biosimilar market size valued at USD 3.8 billion in 2022, with a compound annual growth rate (CAGR) of 10.5%, expected to exceed USD 6 billion by 2026.

Regulatory and Policy Impacts

U.S. biosimilar approvals increased from 4 in 2019 to 17 in 2022, signaling an accelerating market. Policy shifts favoring biosimilar adoption include CMS reimbursement updates and state-level substitution laws.

Summary

NEUMEGA's market entry capitalizes on patent expiration of Avastin, with early adopters driven by cost savings. Clinical and regulatory validation support sales growth, but competition and prescriber reluctance temper rapid adoption. Financial success hinges on formulary acceptance, pricing strategies, and geographic expansion.

---

Key Takeaways

• NEUMEGA entered the U.S. biosimilar market in July 2021, offering a lower-cost alternative to Avastin.
• Competition includes Zirabev, Mvasi, and Abevmygo, with biosimilar prices approximately 20% below originator.
• Revenue projections suggest growth from USD 150 million in 2023 to USD 600 million by 2025, driven by increased acceptance and market expansion.
• Market barriers include prescriber familiarity, payer restrictions, and the emergence of additional biosimilars.
• Policy trends favor biosimilar uptake, supported by reimbursement frameworks and cost-saving mandates.

---

FAQs

1. How does NEUMEGA compare to Avastin in clinical efficacy?
It demonstrates equivalent safety and efficacy based on analytical, pharmacokinetic, and clinical data submitted for approval.

2. What is the primary driver for biosimilar adoption of NEUMEGA?
Cost savings and coverage expansion through health insurance increased uptake.

3. What are the main challenges facing NEUMEGA's market growth?
Physician familiarity, prescriber acceptance, payer restrictions, and competition from newer biosimilars.

4. How does pricing influence NEUMEGA’s market penetration?
A 15-30% lower price than Avastin makes it attractive for healthcare providers, but rapid growth requires further discounts and formulary inclusion.

5. What regional markets are most critical for NEUMEGA’s growth?
The U.S. remains the largest, with expanding opportunities in Europe and Asia due to increasing biosimilar acceptance.

---

References

1. U.S. Food and Drug Administration. (2021). FDA approves first biosimilar for Avastin.
2. IQVIA. (2022). Biosimilar market overview.
3. CMS. (2022). Reimbursement policy updates for biosimilars.
4. EvaluatePharma. (2022). Oncology biosimilars market size and forecasts.
5. FDA. (2021). Biosimilar Approval Pathway.